DE69321729D1 - Aminosäure-gebundene senfgas derivate und ihre verwendung als wirkstoffvorstufe in der behandlung von tumoren - Google Patents

Aminosäure-gebundene senfgas derivate und ihre verwendung als wirkstoffvorstufe in der behandlung von tumoren

Info

Publication number
DE69321729D1
DE69321729D1 DE69321729T DE69321729T DE69321729D1 DE 69321729 D1 DE69321729 D1 DE 69321729D1 DE 69321729 T DE69321729 T DE 69321729T DE 69321729 T DE69321729 T DE 69321729T DE 69321729 D1 DE69321729 D1 DE 69321729D1
Authority
DE
Germany
Prior art keywords
binded
tumors
treatment
amino acid
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69321729T
Other languages
English (en)
Other versions
DE69321729T2 (de
Inventor
Philip John Burke
Robert Ian Dowell
Anthony Mauger
Caroline Springer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Syngenta Ltd
Original Assignee
Cancer Research Campaign Technology Ltd
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929215636A external-priority patent/GB9215636D0/en
Priority claimed from GB939310884A external-priority patent/GB9310884D0/en
Application filed by Cancer Research Campaign Technology Ltd, Zeneca Ltd filed Critical Cancer Research Campaign Technology Ltd
Publication of DE69321729D1 publication Critical patent/DE69321729D1/de
Application granted granted Critical
Publication of DE69321729T2 publication Critical patent/DE69321729T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/54—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
DE69321729T 1992-07-23 1993-07-23 Aminosäure-gebundene senfgas derivate und ihre verwendung als wirkstoffvorstufe in der behandlung von tumoren Expired - Fee Related DE69321729T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929215636A GB9215636D0 (en) 1992-07-23 1992-07-23 Chemical compounds
GB939310884A GB9310884D0 (en) 1993-05-26 1993-05-26 Chemical compounds
PCT/GB1993/001560 WO1994002450A1 (en) 1992-07-23 1993-07-23 Amino acid linked nitrogen mustard derivatives and their use as prodrugs in the treatment of tumours

Publications (2)

Publication Number Publication Date
DE69321729D1 true DE69321729D1 (de) 1998-11-26
DE69321729T2 DE69321729T2 (de) 1999-03-18

Family

ID=26301303

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69321729T Expired - Fee Related DE69321729T2 (de) 1992-07-23 1993-07-23 Aminosäure-gebundene senfgas derivate und ihre verwendung als wirkstoffvorstufe in der behandlung von tumoren

Country Status (25)

Country Link
US (6) US5405990A (de)
EP (1) EP0651740B1 (de)
JP (1) JP3541037B2 (de)
KR (1) KR100268654B1 (de)
AT (1) ATE172450T1 (de)
AU (1) AU681349B2 (de)
CA (1) CA2101104C (de)
CZ (1) CZ287028B6 (de)
DE (1) DE69321729T2 (de)
DK (1) DK0651740T3 (de)
ES (1) ES2123662T3 (de)
FI (1) FI115048B (de)
GB (1) GB9314960D0 (de)
HK (1) HK1002683A1 (de)
HU (1) HUT69288A (de)
IL (1) IL106459A (de)
MY (1) MY111635A (de)
NZ (1) NZ254864A (de)
PH (1) PH30004A (de)
PL (1) PL174617B1 (de)
RU (1) RU2129542C1 (de)
SK (1) SK281338B6 (de)
TW (1) TW272971B (de)
WO (1) WO1994002450A1 (de)
ZW (1) ZW9293A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9314960D0 (en) * 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
US5728868A (en) * 1993-07-15 1998-03-17 Cancer Research Campaign Technology Limited Prodrugs of protein tyrosine kinase inhibitors
GB9315494D0 (en) * 1993-07-27 1993-09-08 Springer Caroline Improvements relating to prodrugs
GB9415167D0 (en) * 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
GB9426133D0 (en) * 1994-12-23 1995-02-22 Zeneca Ltd Chemical compounds
GB9501052D0 (en) 1995-01-19 1995-03-08 Cancer Res Campaign Tech Improvements relating to prodrugs
GB9510830D0 (en) * 1995-05-27 1995-07-19 Zeneca Ltd Proteins
GB9517001D0 (en) * 1995-08-18 1995-10-18 Denny William Enediyne compounds
GB9516943D0 (en) * 1995-08-18 1995-10-18 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs
WO1997034634A1 (en) * 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US6130237A (en) * 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
JP4812167B2 (ja) * 1999-02-12 2011-11-09 モレキュラー インサイト ファーマスーティカルズ インコーポレイテッド 薬物輸送用マトリックス、ならびにその作成方法および使用方法
GB9907414D0 (en) 1999-03-31 1999-05-26 Cancer Res Campaign Tech Improvements relating to prodrugs
US6765019B1 (en) * 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
GB0001653D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Uk Ltd Chemical compound
WO2001078626A1 (en) 2000-04-13 2001-10-25 Sts Biopolymers, Inc. Targeted therapeutic agent release devices and methods of making and using the same
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
WO2002008174A1 (en) * 2000-07-26 2002-01-31 Patrick Anthony Riley Phenylethylamine derivatives and their use in the treatment of melanoma
GB0102239D0 (en) * 2001-01-29 2001-03-14 Cancer Res Ventures Ltd Methods of chemical synthisis
CN101671335A (zh) 2001-05-31 2010-03-17 梅达莱克斯公司 细胞毒素、其有用的前体药物、连接基团和稳定剂
CN1617875A (zh) * 2001-12-13 2005-05-18 兰贝克赛实验室有限公司 结晶二水合头孢地尼钾
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
ATE491725T1 (de) 2002-07-15 2011-01-15 Univ Texas Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
US20040092735A1 (en) * 2002-11-08 2004-05-13 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of cefuroxime sodium
EP1654221A2 (de) * 2003-06-10 2006-05-10 Smithkline Beecham Corporation Von anilin abgeleitete modulatoren von androgen-, glucocorticoid-, mineralcorticoid- und progesteronrezeptoren
EP1648512A4 (de) 2003-07-31 2009-01-21 Immunomedics Inc Anti-cd19 antikörper
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
BRPI0510909A2 (pt) * 2004-05-19 2008-12-16 Medarex Inc composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
AU2006294554B2 (en) * 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
ES2375843T3 (es) 2005-10-26 2012-03-06 Medarex, Inc. Procedimientos y compuestos para la preparación de an�?logos de cc-1065.
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
KR20150067395A (ko) 2006-12-01 2015-06-17 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
NZ578354A (en) 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
AR065404A1 (es) 2007-02-21 2009-06-03 Medarex Inc Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero
NZ586053A (en) 2007-11-09 2012-09-28 Peregrine Pharmaceuticals Inc Anti-vegf antibody compositions and methods
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
EP3122757B1 (de) 2014-02-28 2023-09-06 Hangzhou Dac Biotech Co., Ltd Geladene linker und deren verwendungen zur konjugation
CN113350518A (zh) 2015-07-12 2021-09-07 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
JP7138350B2 (ja) 2016-11-14 2022-09-16 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 共役連結体、該連結体を含有する細胞結合分子－薬物共役体、並びに該共役体及び連結体の使用及び製造方法
CN110494416A (zh) * 2017-05-15 2019-11-22 旭化成株式会社 异氰酸酯的制造方法
CN113845448B (zh) * 2021-10-20 2023-07-07 厦门大学 一种放射性18f标记化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
GB8820850D0 (en) * 1988-09-05 1988-10-05 Cancer Res Campaign Tech Improvements relating to pro-drugs
GB8920011D0 (en) * 1989-09-05 1989-10-18 Mann J New route of synthesis for tertiary butyl esters
WO1993008288A1 (en) * 1991-10-23 1993-04-29 Cancer Research Campaign Technology Limited Bacterial nitroreductase for the reduction of cb 1954 and analogues thereof to a cytotoxic form
GB9314960D0 (en) * 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
CA2101104A1 (en) 1994-01-24
EP0651740A1 (de) 1995-05-10
US5405990A (en) 1995-04-11
JP3541037B2 (ja) 2004-07-07
GB9314960D0 (en) 1993-09-01
DK0651740T3 (da) 1999-06-28
JPH07509461A (ja) 1995-10-19
PL174617B1 (pl) 1998-08-31
WO1994002450A1 (en) 1994-02-03
FI950230A (fi) 1995-01-19
ZW9293A1 (en) 1994-03-30
PL307226A1 (en) 1995-05-15
AU681349B2 (en) 1997-08-28
HK1002683A1 (en) 1998-09-11
FI950230A0 (fi) 1995-01-19
IL106459A (en) 1998-02-08
IL106459A0 (en) 1994-11-11
TW272971B (de) 1996-03-21
US5660829A (en) 1997-08-26
DE69321729T2 (de) 1999-03-18
NZ254864A (en) 1996-11-26
RU2129542C1 (ru) 1999-04-27
EP0651740B1 (de) 1998-10-21
US5587161A (en) 1996-12-24
AU4715693A (en) 1994-02-14
CA2101104C (en) 2007-01-23
FI115048B (fi) 2005-02-28
US6277880B1 (en) 2001-08-21
PH30004A (en) 1996-10-29
US5714148A (en) 1998-02-03
RU95105246A (ru) 1997-04-27
SK6995A3 (en) 1995-07-11
KR100268654B1 (ko) 2000-10-16
CZ15195A3 (en) 1995-11-15
SK281338B6 (sk) 2001-02-12
ATE172450T1 (de) 1998-11-15
CZ287028B6 (en) 2000-08-16
US5958971A (en) 1999-09-28
ES2123662T3 (es) 1999-01-16
HUT69288A (en) 1995-09-28
MY111635A (en) 2000-10-31
HU9500145D0 (en) 1995-03-28

Similar Documents

Publication Publication Date Title
DE69321729T2 (de) Aminosäure-gebundene senfgas derivate und ihre verwendung als wirkstoffvorstufe in der behandlung von tumoren
TR200100918T2 (tr) Aril ve heteroaril sübstitüentli üreler kullanılarak RAF kinazın inhibe edilmesi
ATE224888T1 (de) Pyridylalken- und pyridylalkin-säureamide als cytostatika und immunosuppressive arzneimittel
CY1111504T1 (el) Αζαδικυκλοαλκανια ως ρυθμιστες του ccr5
DE69520499T2 (de) Histidine und homohistidine derivate zur verwendung als protein farnesyltransferase hemmstoffe
HUT76511A (en) Benzoyl derivatives, preparation and use thereot
CA2290520A1 (en) Inhibition of p38 kinase activity by aryl ureas
DE69709407D1 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
ATE299495T1 (de) Aryl-substituierte pyridylalkan-, alken-, und alkin- carboxamidderivate, verwendbar als zytostatische und immunosuppressive mittel
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
ATE171170T1 (de) 7-äther-taxol ähnliche verbindungen antineoplastische verwendung und diese enthaltende pharmazeutische zusammenstellungen
ATE233754T1 (de) Diphenyl-piperidin derivate
TR199700711T1 (xx) Ciltten ge�erek v�cuda giren form�lasyon.
ATE384708T1 (de) Piperazinderivate als aktivitätsmodulatoren der chemokinrezeptoren
ES2134778T3 (es) Bistriazenos como agentes quimioterapeuticos.
ATE182077T1 (de) Benzazole derivate als therapeutische mittel
DK0773782T3 (da) Terpenderivater (sarcodictyiner) anvendelse som antitumormidler
TR199903272T2 (xx) Ast�m kar��t� ila�lar�n yeni bile�imleri.
FR2789588B1 (fr) Utilisation d'une proteine ompa d'enterobacterie associee a un antigene dans une composition pharmaceutique destinee a generer ou accroitre une reponse cytotoxique antivirale, antiparasitaire ou antitumorale
ATE306483T1 (de) Alkoxy-substituierte benzimidazolverbindungen , diese enthaltende arzneimittel und ihre verwendung
DE50200757D1 (de) Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren
PL318351A1 (en) Benzoyl derivatives and their synthesis
AU2003266031A1 (en) Pomolic acid, its isomers, derivatives and their uses, pharmaceutical composition method to prepare the pharmaceutical composition and method for treating multidrug resistant tumours

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee